GRTX Galera Therapeutics, Inc. Stock Quote

GRTX [NASD]

Index	-	P/E	-	EPS (ttm)	-3.13	Insider Own	0.60%	Shs Outstand	26.45M	Perf Week	36.00%
Market Cap	37.49M	Forward P/E	-	EPS next Y	-0.71	Insider Trans	17.81%	Shs Float	25.35M	Perf Month	-16.67%
Income	-80.50M	PEG	-	EPS next Q	-0.57	Inst Own	45.30%	Short Float	2.55%	Perf Quarter	-34.11%
Sales	-	P/S	-	EPS this Y	-4.60%	Inst Trans	16.83%	Short Ratio	2.83	Perf Half Y	1.19%
Book/sh	-2.19	P/B	-	EPS next Y	34.30%	ROA	-87.60%	Target Price	12.25	Perf Year	-79.01%
Cash/sh	3.23	P/C	0.53	EPS next 5Y	45.70%	ROE	234.70%	52W Range	1.15 - 10.79	Perf YTD	-62.96%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-84.24%	Beta	-
Dividend %	-	Quick Ratio	6.00	Sales past 5Y	-	Gross Margin	-	52W Low	47.83%	ATR	0.20
Employees	30	Current Ratio	6.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	47.50	Volatility	17.61% 12.79%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	21.00%	Profit Margin	-	Rel Volume	0.50	Prev Close	1.69
Shortable	Yes	LT Debt/Eq	-	Earnings	Mar 10 BMO	Payout	-	Avg Volume	228.32K	Price	1.70
Recom	1.70	SMA20	1.46%	SMA50	-17.20%	SMA200	-56.01%	Volume	115,824	Change	0.59%

Oct-19-21

Downgrade

BTIG Research

Buy → Neutral

Oct-19-21

Downgrade

BofA Securities

Buy → Underperform

$17 → $2

Apr-26-21

Resumed

Credit Suisse

Outperform

$15

Dec-16-20

Upgrade

Credit Suisse

Neutral → Outperform

$9 → $15

Dec-07-20

Initiated

H.C. Wainwright

Buy

$15

Dec-02-19

Initiated

Credit Suisse

Neutral

Dec-02-19

Initiated

Citigroup

Buy

Dec-02-19

Initiated

BTIG Research

Buy

Dec-02-19

Initiated

BofA/Merrill

Buy

May-16-22 02:25PM	Galera shares surge on news it will seek OK for lead drug candidate by year's end American City Business Journals +13.25%
07:30AM	Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates GlobeNewswire
07:00AM	Galera Announces Plan to Submit Avasopasem NDA by Year End GlobeNewswire
May-02-22 07:00AM	Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis GlobeNewswire +10.06%
Apr-27-22 10:00AM	Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire -5.35%
Mar-21-22 06:34PM	Can Galera Therapeutics (NASDAQ:GRTX) Afford To Invest In Growth? Simply Wall St.
Mar-10-22 07:00AM	Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates GlobeNewswire
Jan-06-22 07:00AM	Galera to Present at H.C. Wainwright BioConnect Conference GlobeNewswire
Dec-15-21 08:30AM	Are Options Traders Betting on a Big Move in Galera (GRTX) Stock? Zacks +7.41%
Dec-14-21 01:06PM	Galera shares double after firm announces 'corrected' study results for its lead drug candidate American City Business Journals +95.65%
11:31AM	GRTX Stock Alert: The Surprising News That Has Galera Therapeutics Going Gangbusters Today InvestorPlace
10:51AM	Why Galera Shares Are Surging More Than Double Today? Benzinga
07:00AM	Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem GlobeNewswire
05:22AM	Galera Therapeutics Surges After Corrected Trial Data Investing.com
Nov-16-21 09:08AM	Coherus' (CHRS) Toripalimab Gets Orphan Drug Tag for Rare Cancer Zacks
Nov-15-21 07:00AM	Galera to Present at Two Upcoming Investor Conferences in November GlobeNewswire
Nov-10-21 07:00AM	Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates GlobeNewswire
Nov-02-21 09:04AM	Galera Therapeutics, Inc. (GRTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Zacks
Oct-28-21 07:23AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday InvestorPlace -17.01%
Oct-25-21 02:39PM	How The Future Looks For Last Week's Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More Benzinga
Oct-21-21 12:00PM	All You Need to Know About Galera Therapeutics, Inc. (GRTX) Rating Upgrade to Buy Zacks -5.63%
Oct-20-21 10:16AM	Galera (GRTX) Tanks As Oral Mucositis Study Fails to Meet Goal Zacks -5.33%
Oct-19-21 12:11PM	Mid-Day Market Update: Silver Surges 3%; Galera Therapeutics Shares Plunge Benzinga -69.59%
07:00AM	Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis GlobeNewswire
Oct-15-21 08:23AM	What Type Of Shareholders Make Up Galera Therapeutics, Inc.'s (NASDAQ:GRTX) Share Registry? Simply Wall St.
Oct-12-21 07:00AM	Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer GlobeNewswire
Oct-05-21 02:52PM	Here's why local stocks are slightly underperforming the S&P 500 this year American City Business Journals +5.87%
Sep-14-21 07:00AM	Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer GlobeNewswire
Sep-08-21 07:00AM	Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters GlobeNewswire
Sep-07-21 07:00AM	Galera to Present at Three Upcoming Investor Conferences in September GlobeNewswire
Aug-16-21 08:01AM	Is Galera Therapeutics (NASDAQ:GRTX) In A Good Position To Invest In Growth? Simply Wall St.
Aug-10-21 07:00AM	Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments GlobeNewswire
Jun-28-21 07:00AM	Galera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Severe Oral Mucositis GlobeNewswire
Jun-03-21 04:00AM	Should You Take Comfort From Insider Transactions At Galera Therapeutics, Inc. (NASDAQ:GRTX)? Simply Wall St.
May-26-21 07:00AM	Galera to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-17-21 07:00AM	Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer GlobeNewswire
May-12-21 04:01PM	Science Translational Medicine Article Shows Galeras Selective Dismutase Mimetic Synergizes with Radiotherapy to Ablate Tumors GlobeNewswire
May-11-21 07:00AM	Galera Reports First Quarter 2021 Financial Results and Recent Accomplishments GlobeNewswire +7.73%
May-05-21 07:00AM	Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference GlobeNewswire -6.62%
Apr-29-21 06:28AM	Galera Therapeutics Stock Surges After Its Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study Benzinga +22.84%
Apr-28-21 04:01PM	Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer GlobeNewswire
Mar-11-21 07:00AM	Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Accomplishments GlobeNewswire
Mar-10-21 08:00AM	Galera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference GlobeNewswire
Feb-19-21 02:39AM	We Think Galera Therapeutics (NASDAQ:GRTX) Needs To Drive Business Growth Carefully Simply Wall St.
Dec-07-20 04:26PM	Is GRTX A Good Stock To Buy Now? Insider Monkey
Nov-20-20 08:00AM	Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire
Nov-10-20 07:00AM	Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates GlobeNewswire
Nov-03-20 08:00AM	Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference GlobeNewswire +19.45%
Oct-27-20 03:00PM	Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer GlobeNewswire -9.84%
Oct-23-20 05:00PM	Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic Cancer GlobeNewswire
Oct-22-20 08:00AM	Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer GlobeNewswire
Oct-20-20 10:02AM	How Many Galera Therapeutics, Inc. (NASDAQ:GRTX) Shares Do Institutions Own? Simply Wall St.
Sep-22-20 08:00AM	Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer GlobeNewswire
Sep-16-20 08:00AM	Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19 GlobeNewswire
Sep-14-20 08:00AM	Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit GlobeNewswire -5.15%
Sep-08-20 08:00AM	Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBRT for Locally Advanced Pancreatic Cancer GlobeNewswire +9.89%
Aug-10-20 07:00AM	Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates GlobeNewswire
Jul-30-20 08:00AM	Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference GlobeNewswire
Jul-22-20 02:35PM	Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely? Simply Wall St.
Jul-13-20 05:46PM	Galera Therapeutics Completes Enrollment of Phase 1b/2a Clinical Trial of GC4419 in Combination with Radiotherapy for Locally Advanced Pancreatic Cancer GlobeNewswire
Jun-10-20 02:55PM	Hedge Funds Are Selling Galera Therapeutics, Inc. (GRTX) Insider Monkey -5.05%
May-29-20 08:00AM	Galera Therapeutics Announces Avasopasem Manganese Improved Markers of Chronic Kidney Disease in Patients Receiving Cisplatin GlobeNewswire
May-18-20 04:05PM	Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease GlobeNewswire
May-13-20 05:19PM	Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease to be Presented at ASCO 2020 Virtual Scientific Program GlobeNewswire -7.21%
May-12-20 07:00AM	Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates GlobeNewswire
May-05-20 08:00AM	Galera Therapeutics to Present at BofA Securities 2020 Health Care Conference GlobeNewswire -12.22%
Apr-30-20 04:15PM	Galera Therapeutics Announces Presentation of Avasopasem Manganese Data at ASCO 2020 Virtual Scientific Program GlobeNewswire -5.20%
Apr-02-20 08:00AM	Galera Therapeutics Appoints Linda B. West to Board of Directors GlobeNewswire
Mar-10-20 07:00AM	Galera Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments GlobeNewswire
Feb-27-20 04:05PM	Galera Therapeutics Announces Avasopasem Manganese (GC4419) Maintained Anti-Cancer Benefit of Chemoradiotherapy for Head and Neck Cancer While Substantially Reducing Radiation-Induced Severe Oral Mucositis GlobeNewswire +5.49%
Feb-24-20 08:00AM	Galera Therapeutics Announces Presentation of Avasopasem Manganese (GC4419) Two-Year Tumor Outcomes Data at 2020 Multidisciplinary Head and Neck Cancers Symposium GlobeNewswire -7.38%
Feb-19-20 08:00AM	Galera Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference GlobeNewswire +7.04%
Jan-07-20 04:40PM	Galera Therapeutics Announces Dosing of First Patient in Phase 2a Clinical Trial of Avasopasem Manganese (GC4419) in Second Indication GlobeNewswire +7.93%
Dec-17-19 08:00AM	3 Strong Buy Healthcare Stocks That Can Double in 2020 TipRanks +11.80%
Dec-10-19 07:00AM	Galera Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update GlobeNewswire -5.00%
Dec-05-19 05:18PM	Galera Therapeutics Announces Publication of GC4419 Data in the Journal of Clinical Oncology GlobeNewswire -9.17%
Dec-02-19 01:10PM	Analysts: Galera Has Novel Pipeline For Radiation Oncology Market, Commercialization Remains Headwind Benzinga
Nov-06-19 07:26PM	Galera Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Beardsley Robert A	Chief Operating Officer	Dec 17	Option Exercise	1.07	20,000	21,400	88,191	Dec 20 06:30 PM
West Linda	Director	Dec 17	Buy	2.74	20,000	54,804	60,000	Dec 20 06:30 PM
HOLMLUND JON T	Chief Medical Officer	Sep 01	Option Exercise	2.43	47,756	116,047	47,756	Sep 03 04:31 PM
HOLMLUND JON T	Chief Medical Officer	Sep 01	Sale	8.47	47,756	404,498	0	Sep 03 04:31 PM
West Linda	Director	Jun 15	Buy	9.13	10,000	91,300	40,000	Jun 17 06:41 PM
West Linda	Director	Jun 02	Buy	8.65	10,000	86,511	30,000	Jun 04 08:13 PM
Alleva Lawrence M	Director	Jun 01	Buy	8.59	4,045	34,741	4,045	Jun 03 05:22 PM
West Linda	Director	Jun 01	Buy	8.64	10,000	86,381	20,000	Jun 02 05:35 PM
West Linda	Director	May 28	Buy	8.64	10,000	86,410	10,000	Jun 02 05:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience